lung cancer

[Cullinan Oncology, Inc.] Cullinan Oncology, Inc. reported updated data from the Company’s ongoing Phase I/IIa trial of CLN-081 in non-small cell lung cancer patients whose tumors harbor epidermal growth factor receptor exon 20 insertion mutations that have progressed on or after prior therapy.

[Frontiers in Cell and Developmental Biology] Scientists found that halofuginone inhibited the proliferation, induced G0/G1 phase arrest, and promoted apoptosis in lung cancer cells in a dose-dependent manner.

[Cold Spring Harbor Perspectives in Medicine] Work in model systems has provided insights into the biology of lung cancer subtypes and their origins, contributed to our understanding of the mechanisms that underlie tumor progression, and revealed new therapeutic vulnerabilities.

[Communications Biology] Researchers presented a small-molecule compound D6 which selectively inhibited tumor cell growth and migration in NSCLC cells with EGFR-TKI-resistant T790M-EGFR-activated mutations.

[Molecular Therapy-Nucleic Acids] Using unbiased transcriptome profiling of hypoxia-preconditioned MSCs and normoxic MSCs, scientists identified a lncRNA named lung cancer-associated transcript 1 (LUCAT1) under hypoxia.

[Acta Pharmacologica Sinica] Researchers investigated how schlafen family member 11 (SLFN11) expression regulated the sensitivity of small cell lung cancer to topotecan.